Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumors × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 8 Recurrence 3 Ovarian Neoplasms 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Radiation Pneumonitis 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Ovarian Diseases 1 Oligodendroglioma 1 Neoplasms by Site 1 Neoplasms 1 Mesothelioma, Malignant 1 Melanoma, Cutaneous Malignant 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Esophagogastric Adenocarcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1

Interventions

Sunitinib 4 Cyclophosphamide 4 Capecitabine 4 Bevacizumab 4 pazopanib 3 Topotecan 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 temsirolimus 2 liposomal doxorubicin 2 fludarabine 2 Sorafenib 2 Panobinostat 2 NVP-BKM120 2 Lapatinib 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Bortezomib 2 vadimezan 1 spartalizumab 1 somatostatin receptor 2 1 selinexor 1 selicrelumab 1 perifosine 1 pegylated granulocyte colony-stimulating factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01349296 2016-05-20

BARIS

University of Cologne

Phase 1 Completed

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡